Fluoxetine, smoking, and history of major depression: A randomized controlled trial

Journal of Consulting and Clinical Psychology

Volumn 75, Issue 1, 2007, Pages 85-94

  Spring, Bonnie ^a,b,c,d   Doran, Neal ^a   Pagoto, Sherry ^a   McChargue, Dennis ^a   Cook, Jessica Werth ^a   Bailey, Katherine ^a   Crayton, John ^b   Hedeker, Donald ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Depression; Fluoxetine; Randomized controlled trial; Smoking cessation; Tobacco

Indexed keywords

FLUOXETINE; NORFLUOXETINE; PLACEBO;

ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SMOKING;

EID: 33846984990     PISSN: 0022006X     EISSN: None     Source Type: Journal    
DOI: 10.1037/0022-006X.75.1.85     Document Type: Article

References (61)

1. Ahluwalia, J. S., Harris, K. J., Catley, D., Okuyemi, K. S., & Mayo, M. S. (2002). Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial. Journal of the American Medical Association, 288, 468-474.
2. Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
3. Blondal, T., Gudmundsson, L. J., Tomasson, K., Jonsdottir, D., Hilmarsdottir, H., Kristjansson, F., et al. (1999). The effects of fluoxetine combined with nicotine inhalers in smoking cessation: A randomized trial. Addiction, 94, 1007-1015.
4. Borrelli, B., Marcus, B. H., Clark, M. M., Bock, B. C., King, T. K., & Roberts, M. (1999). History of depression and subsyndromal depression in women smokers. Addictive Behaviors, 24, 781-794.
5. Borrelli, B., Niaura, R., Keuthen, N. J., Goldstein, M. G., DePue, J. D., Murphy, C., & Abrams, D. B. (1996). Development of major depressive disorder during smoking-cessation treatment. Journal of Clinical Psychiatry, 57, 534-538.
6. Bowen, D. J., Spring, B., & Fox, E. (1991). Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy. Journal of Behavioral Medicine,14, 97-110.
7. Cornelius, J. R., Perkins, K. A., Salloum, I. M., Thase, M. E., & Moss, H. B. (1999). Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients. Journal of Clinical Psychopharmacology, 19, 183-184.
8. Corrigall, W. A. (1991). Understanding brain mechanisms in nicotine reinforcement. British Journal of Addiction, 86, 507-510.
9. Covey, L. (2004). Comments on "History of depression and smoking cessation outcome: A meta-analysis." Nicotine and Tobacco Research, 6, 743-745.
10. Covey, L. S., Glassman, A. H., & Stetner, F. (1990). Depression and depressive symptoms in smoking cessation. Comprehensive Psychiatry, 31, 350-354.
11. Covey, L. S., Glassman, A. H., Stetner, F., Rivelli, S., & Stage, K. (2002). A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. American Journal of Psychiatry, 159, 731-737.
12. Dalack, G. W., Glassman, A. H., Rivelli, S., Covey, L., & Stetner, F. (1995). Mood, major depression, and fluoxetine response in cigarette smokers. American Journal of Psychiatry, 152, 398-403.
13. Diggle, P. J., Heagerty, P., Liang, K. Y., & Zeger, S. L. (2002). Analysis of longitudinal data. New York: Oxford University Press.
14. Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998). Dramatic decreases in brain reward function during nicotine withdrawal. Nature, 393, 76-79.
15. First, M. B., Gibbon, M., Spitzer, R. L., & Williams, J. (Writers). (1996). Training video for the structured clinical interview for DSM-IV Axis I disorders [Motion Picture]. (Available from the New York State Psychiatric Research Institute, 1051 Riverside Drive, New York, NY 10032)
16. Gamberino, W. C., & Gold, M. S. (1999). Neurobiology of tobacco smoking and other addictive disorders. Psychiatric Clinics of North America, 22, 301-312.
17. Glassman, A. H. (1997). Cigarette smoking and its comorbidity. NIDA Research Monographs, 172(Whole).
18. Hall, S. M., Humfleet, G. L., Reus, V. I., Munoz, R. F., & Cullen, J. (2004). Extended nortriptyline and psychological treatment for cigarette smoking. American Journal of Psychiatry, 161, 2100-2107.
19. Hall, S. M., Humfleet, G. L., Reus, V. I., Munoz, R. F., Hartz, D. T., Maude-Griffin, R. (2002). Psychological intervention and antidepressant treatment in smoking cessation. Archives of General Psychiatry, 59, 929-937.
20. Hall, S. M., Munoz, R. F., & Reus, V. I. (1994). Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. Journal of Consulting and Clinical Psychology, 62, 141-146.
21. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
22. Harrison, A., Liem, Y. T. B., & Markou, A. (2001). Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology, 25, 55-71.
23. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerstrom, K. O. (1991). The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
24. Hitsman, B., Borrelli, B., McChargue, D. E., Spring, B., & Niaura, R. (2003). History of depression and smoking cessation outcome: A metaanalysis. Journal of Consulting and Clinical Psychology, 71, 657-663.
25. Hitsman, B., Pingitore, R., Spring, B., Mahableshwarkar, A., Mizes, J. S., Segraves, K. A., et al. (1999). Antidepressant pharmacotherapy helps some cigarette smokers more than others. Journal of Consulting and Clinical Psychology, 67, 547-554.
26. Hitsman, B., Spring, B., Borrelli, B., McChargue, D., & Niaura, R. (2004). Response to Covey. Nicotine and Tobacco Research, 6, 747-749.
27. Hsieh, F. Y. (1988). Sample size formulae for intervention studies with the cluster as unit of randomization. Statistics in Medicine, 7, 1195-1201.
28. Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., & Swan, G. E. (2003). Measures of abstinence in clinical trials: Issues and recommendations. Nicotine and Tobacco Research, 5, 13-25.
29. Hughes, J. R., Stead, L. F., & Lancaster, T. (2005). Nortriptyline for smoking cessation: A review. Nicotine and Tobacco Research, 7, 491-499.
30. Ichikawa, J., Kuroki, T., & Meltzer, H. (1998). Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. European Journal of Pharmacology, 350, 159-164.
31. Ichikawa, J., & Meltzer, H. (1995). Effect of antidepressants on striatal and accumbens extracellular dopamine levels. European Journal of Pharmacology, 281, 255-261.
32. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340, 685-691.
33. Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002). Discontinuation symptoms: Comparison of brief interruption in fluoxetine and paroxetine treatment. International Clinical Psychopharmacology, 17, 217-225.
34. Kapur, S. (1992). Riboflavin as a marker of medication compliance. Schizophrenia Research, 6, 49.
35. Killen, J. D., Fortmann, S. P., Kraemer, H. C., Varady, A. N., Davis, L., & Newman, B. (1996). Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse. Journal of Consulting and Clinical Psychology, 64, 1060-1067.
36. Killen, J. D., Fortmann, S. P., Schatzberg, A. F., Hayward, C., Sussman, L., Rothman, M., et al. (2000). Nicotine patch and paroxetine for smoking cessation. Journal of Consulting and Clinical Psychology, 68, 883-889.
37. Killen, J. D., Fortmann, S. P., Schatzberg, A., Hayward, C., & Varady, A. (2003). Onset of major depression during treatment for nicotine dependence. Addictive Behaviors, 28, 461-470.
38. Koran, L. M., Cain, J. W., Dominguez, R. A., Rush, A. J., & Thiemann, S. (1996). Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? American Journal of Psychiatry, 153, 1450-1455.
39. Korsgaard, S., Gerlach, J., Christensson, E. (1985). Behavioral aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology, 118, 245-252.
40. Kraemer, H. C., & Kupfer, D. J. (2006). Size of treatment effects and their importance to clinical research and practice. Biological Psychiatry, 59, 990-996.
41. Lagakos, S. W. (2006). Time-to-event analyses for long-term treatments: The APPROVe trial. New England Journal of Medicine, 355, 113-117.
42. Liang, K. Y., & Zeger, S. L. (1986). Longitudinal data analysis using generalized linear models. Biometrika, 73, 13-22.
43. Markou, A., Kosten, T. R., Koob, G. F. (1998). Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology, 18, 135-174.
44. McQuay, H. J., & Moore, R. A. (1997). Using numerical results from systematic reviews in clinical practice. Annals of Internal Medicine, 126, 712-720.
45. Naranjo, C. A., Kadlec, K. E., Sanhueza, P., Woodley-Remus, D., & Sellers, E. M. (1990). Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology and Therapeutics, 47, 490-498.
46. Nash, J. F., Bopp, R. J., Carmichael, R. H., Farid, K. Z., & Lemberger, L. (1982). Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection. Clinical Chemistry, 28, 2100-2102.
47. Niaura, R., Spring, B., Borrelli, B., Hedeker, D., Goldstein, M. G., Keuthen, N., et al. (2002). Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. Journal of Consulting and Clinical Psychology, 70, 887-896.
48. Pomerleau, O. F., Pomerleau, C. S., Snedecor, S. M., Gaulrapp, S., Brouwer, R. N., & Cameron. O. G. (2004). Depression, smoking abstinence and HPA function in women smokers. Human Psychopharmacology: Clinical and Experimental, 19, 467-476.
49. Rausch, J. L., Nichinson, B., Lamke, C., & Matloff, J. (1990). Influence of negative affect on smoking cessation treatment outcome: A pilot study. British Journal of Addiction, 85, 929-933.
50. Saules, K. K., Schuh, L. M., Arfken, C. L., Reed, K., Kilbey, M. M., & Schuster, C. R. (2004). Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. American Journal of Addiction, 13, 438-446.
51. Sellers, E. M., Naranjo, C. A., & Kadlec, K. (1987). Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. Journal of Clinical Psychopharmacology, 7, 417-420.
52. Selzer, M. (1973). A self-administered Short Michigan Alcoholism Screening Test (SMAST). Journal of Studies on Alcohol, 36, 117-126.
53. Spitzer, R. L., Williams, J. B. W., & Gibbon, M. (1994). Structured clinical interview for DSM-IV: Nonpatient version (SCID-NP). New York: New York State Psychiatric Institute.
54. Spring, B. (Writer). (2002). Smoking cessation [Motion picture]. (Available from the American Psychological Association, 750 First Street, NE, Washington, DC 20002-4242)
55. Spring, B. (in press). Cognitive-behavioral treatment to promote smoking cessation plus weight control. New York: Oxford University Press.
56. Spring, B., Hitsman, B., Pingitore, R., McChargue, D. E., Gunnarsdottir, D., Corsica, J., et al. (2007). Effect of tryptophan depletion on smokers and non-smokers with and without a history of major depression. Biological Psychiatry, 61, 70-77.
57. Spring, B., Wurtman, J., Gleason, R., Wurtman, R., & Kessler, K. (1991). Weight gain and withdrawal symptoms after smoking cessation: A preventive intervention using d-fenfluramine. Health Psychology, 10, 216-223.
58. Spring, B., Wurtman, J., Wurtman, R., El-Khoury, A., Goldberg, H., McDermott, J., & Pingitore, R. (1995). Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. American Journal of Clinical Nutrition, 62, 1181-1187.
59. Swan, G., Ward, M., & Jack, L. (1996). Abstinence effects as predictors of 28-day relapse in smokers. Addictive Behaviors, 21, 481-490.
60. Tsoh, J. Y., Humfleet, G. L., Munoz, R. F., Reus, V. I., Hartz, D. T., & Hall, S. M. (2000). Development of major depression after treatment for smoking cessation. American Journal of Psychiatry, 157, 368-374.
61. Verbeke, G., & Molenberghs, G. (2000). Linear mixed models for longitudinal data. New York: Springer.